Novel, immune agonistic CEACAM1/5 antibody (YB-200) demonstrates anti-tumor efficacy ...
Updated: Apr 3, 2023
Authors: Katrin Rupalla, Michel Janicot, Alexej Schmidt, Iris Helfrich, Bernhard B. Singer
Full Title: Novel, immune agonistic CEACAM1/5 antibody (YB-200) demonstrates anti-tumor efficacy, and significantly increases tumor-associated B-cell population in syngeneic liver Hepa1-6 tumor microenvironment
This poster was presented at the SITC 2022.
Comments